Could a gene test pick the right blood pressure pill for black patients?

NCT ID NCT04840342

Ongoing Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the drug eplerenone works better than amlodipine for controlling high blood pressure in Black adults who carry a specific gene variant (LSD1 risk allele). About 300 participants will follow a controlled diet and take escalating doses of one of the two drugs for four weeks. The goal is to see if a gene-guided approach can improve blood pressure control and reduce kidney damage in this group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Eplerenone and amlodipine
What this could lead to: If successful, this could point toward a more effective, gene-targeted treatment for high blood pressure in Black patients with a specific genetic variant.
What could go wrong: This is a phase 4 trial with a moderate sample size, but it only includes Black adults with a specific gene variant, so results may not apply to everyone. The study is also not yet recruiting, and outcomes may not lead to a new standard of care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperaldosteronism hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION MINERALOCORTICOID EXCESS

Contacts and locations

Locations

Brigham and Women's

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.